Qualified protein degradation is becoming explored instead method in cancer, whereby the organic protein degradation method is co-opted for therapeutic purposes. Recently created novel molecules known as proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One ligand binds to the ‘protein of fascination’ (POI) and https://www.directivepublications.org/journal-of-clinical-breast-cancer/